Endeavour Silver Corp vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Endeavour Silver Corp trades at $8.72 (market cap $2.54B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.73 (market cap $2.27B). The key difference: Endeavour Silver Corp and SELLAS Life Sciences Group Inc. Common Stock are close in size by market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, Endeavour Silver Corp nearer its low. Which is the better fit depends on your goals.
| EXK | SLS | |
|---|---|---|
Market Cap | $2.54B | $2.27B |
Volume | 7,077,330 | 4,179,659 |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $15.46 |
52-Week Low | $7.07 | $1.39 |
Typical Hold Time | 25 Days | — |
Enterprise Value | $2.54B | $2.14B |
Signals from Pluang's Aura AI — not financial advice
Endeavour Silver (EXK) trades at $8.72, up 4.81% today, showing mixed technical signals with bearish moving averages but neutral oscillators. The company demonstrates improving fundamentals with Q1 2026 earnings beating expectations and projected revenue growth from $468M to $737M in 2026. Recent operational developments include Terronera mine resumption and Kolpa expansion, though mechanical issues at Guanacevi mine present near-term challenges.
EXK presents a growth story with strong analyst support (78.57% buy rating) and improving profitability, but faces operational risks and high valuation multiples. The stock's outlook depends on successful mine execution and silver price stability, with technical resistance at $9.00 providing a near-term hurdle for further upside.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →